Experience with ebrantil used in patients with resistant arterial hypertension in chronic kidney disease
| Autor: | R I Semenova, N S Musina |
|---|---|
| Jazyk: | ruština |
| Rok vydání: | 2012 |
| Předmět: | |
| Zdroj: | Терапевтический архив, Vol 84, Iss 8, Pp 72-74 (2012) |
| Druh dokumentu: | article |
| ISSN: | 0040-3660 2309-5342 |
| Popis: | Summary. Aim. To evaluate the clinical efficacy of ebrantil used in patients with resistant arterial hypertension (RAH) in Stage III-V chronic kidney disease (CKD). Subjects and methods. Sixty-five patients with Stage III-V CKD and RAH (systolic blood pressure (SBP) 215.7±4.0 mm Hg and diastolic blood pressure (DBP) 114.6±2.3 mm Hg) were followed up. The patients received intravenous ebrantil (urapidil) in a dose of 25 mg for 5 days and then were switched to its oral use as 30-60-mg capsules twice daily for 12 weeks. Results. The intravenous infusion caused a significant fall in SBP and DBP by 23.6 and 16.7%, respectively, within 60-90 min. A steady-state antihypertensive effect was achieved on days 5-7 (SBP and DBP was lowered to 146.8±6.1 and 95.6±5.3 mm Hg, respectively; p |
| Databáze: | Directory of Open Access Journals |
| Externí odkaz: |
|